Skip to content
ppharmaranks
Menu

Best treatments for chronic-phase myeloid leukemia

3 products may treat chronic-phase myeloid leukemia, spanning FDA drug classes such as kinase inhibitor. The current highest-rated option is danziten. Ranked below by our independent recall-safety rating (rated where FDA data exists) — not medical advice; always consult a professional.

Quick answer: Of the 3 drugs we list for chronic-phase myeloid leukemia, none are yet flagged as generics in our price data, spanning classes such as kinase inhibitor. They’re ranked by each drug’s FDA recall-safety record — not clinical effectiveness for chronic-phase myeloid leukemia — so confirm the right choice with your prescriber.

Rated against independent regulatory sources·Last updated August 19, 2026·How we rate

Top-rated picks for chronic-phase myeloid leukemia: 1. Danziten · 2. Tasigna · 3. Cavhanza

Top-rated treatments for chronic-phase myeloid leukemia, ranked by pharmaranks score
#DrugRatingPharmacy pays
170/100View →
270/100View →
3Not yet ratedView →

Full ranking · 3 treatments

Frequently asked

What treats chronic-phase myeloid leukemia?
Our catalog lists 3 products that may treat chronic-phase myeloid leukemia, based on NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. They're rated where FDA recall-safety data exists; the current top-rated option is danziten.
What is the best-rated treatment for chronic-phase myeloid leukemia?
By our independent recall-safety rating — not an efficacy measure — danziten ranks highest among the products we list for chronic-phase myeloid leukemia. Always consult a professional.
How are these treatments ranked?
By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.
What types of drugs treat chronic-phase myeloid leukemia?
Treatments for chronic-phase myeloid leukemia span FDA drug classes including kinase inhibitor. Compare every option side by side, ranked by independent rating, above.

Treatment associations are derived from NIH RxClass (MED-RT “may treat”) drug-classification data — not the verbatim FDA label. This is general reference, not medical advice — always consult a licensed professional.